Omega-3 Fatty Acids Increase Amyloid-ß Immunity, Energy, and Circadian Rhythm for Cognitive Protection of Alzheimer's Disease Patients Beyond Cholinesterase Inhibitors.
J Alzheimers Dis
; 75(3): 993-1002, 2020.
Article
em En
| MEDLINE
| ID: mdl-32390637
ABSTRACT
BACKGROUND:
The cholinesterase inhibitor therapeutics (CI) approved for use in Alzheimer's disease (AD) are palliative for a limited time.OBJECTIVE:
To examine the outcome of AD patients with add-on therapy of the omega-3 fatty acid drink Smartfish.METHODS:
We performed a prospective study using Mini-Mental State Examination, amyloid-ß (Aß) phagocytosis blood assay, and RNA-seq of peripheral blood mononuclear cells in 28 neurodegenerative patients who had failed their therapies, including 8 subjective cognitive impairment (SCI), 8 mild cognitive impairment (MCI), 2 AD dementia, 1 frontotemporal dementia (FTD), 2 vascular cognitive impairment, and 3 dementia with Lewy bodies (DLB) patients.RESULTS:
MCI, FTD, and DLB patients patients volunteered for the addition of a ω-3 fatty acid drink Smartfish protected by anti-oxidants to failing CI therapy. On this therapy, all MCI patients improved in the first year energy transcripts, Aß phagocytosis, cognition, and activities of daily living; in the long term, they remained in MCI status two to 4.5 years. All FTD and DLB patients rapidly progressed to dementia. On in vivo or in vitroω-3 treatments, peripheral blood mononuclear cells of MCI patients upregulated energy enzymes for glycolysis and citric acid cycle, as well as the anti-inflammatory circadian genes CLOCK and ARNTL2.CONCLUSION:
Add-on ω-3 therapy to CI may delay dementia in certain patients who had failed single CI therapy.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ácidos Graxos Ômega-3
/
Inibidores da Colinesterase
/
Doença de Alzheimer
Tipo de estudo:
Observational_studies
Idioma:
En
Revista:
J Alzheimers Dis
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos